A.CURE (에이닷큐어)
Category: AI in Healthcare
Voice AI-powered digital healthcare startup developing 'Heart to Voice' for early detection and severity prediction of heart failure through voice analysis A.CURE (에이닷큐어) was founded in 2024. The company is led by 정경호 (Jung Kyung-ho). Based in Seoul, South Korea. Team size: 8. Total funding raised: $500K. Latest round: Seed. Key investors include 인천창조경제혁신센터 (Incheon Creative Economy Innovation Center); 씨엔티테크 (CNT Tech); 더인벤션랩 (The Invention Lab); 임팩트재단 (Impact Foundation); 제이앤피메디파트너스 (J&P Medi Partners).
- Founded
- 2024
- Headquarters
- Seoul, South Korea
- Team size
- 8
- Total funding
- $500K
Value proposition
Non-invasive, voice-based AI solution that detects heart failure and predicts severity by analyzing subtle vocal changes caused by pulmonary congestion, enabling early intervention and continuous remote monitoring
Products and solutions
Heart to Voice (하트 투 보이스) — AI voice analysis-based heart failure detection and severity prediction solution; 90-day prescription monitoring digital medical device for discharged heart failure patients; Insurance-linked heart health risk management service
Unique value
Heart to Voice combines voice analysis with 9 clinical indicators (NT-proBNP, echocardiography, ECG) using unsupervised learning to classify heart failure into 4 stages (normal/mild/moderate/severe), achieving 90.4% AUROC in exploratory studies
Target customer
Hospitals and primary care institutions; Nursing homes and senior care facilities; Discharged heart failure patients (90-day monitoring); Insurance companies (heart health risk management); Senior residences and public health centers
Industries served
Digital Healthcare; Medical AI/Software as Medical Device (SaMD); Senior Care; Insurance/Health Risk Management
Technology advantage
Proprietary AI voice analysis engine with 90.4% AUROC; Patient-specific baseline model using voice + clinical data; Unsupervised learning for 4-stage severity classification; Oracle Cloud Infrastructure (OCI) partnership for scalable deployment; Technology transferred from Korea University Medical Center (2024)
How they differentiate
First-mover in voice-based heart failure AI diagnostics in Korea; Combines voice biomarkers with 9 clinical indicators for multi-modal analysis; Dual-track strategy (regulated medical device + wellness/preventive care); Faculty startup from Korea University Medical Center with strong clinical validation
Main competitors
예지엑스 (YezigX) — EHR/medical imaging multi-modal AI for heart failure readmission prediction; 에봄에이아이 (Ebom AI) — ECG/echocardiography-based AI for early heart disease diagnosis; 메디컬에이아이 (Medical AI) — AI-based heart failure diagnosis solution 'Etia' (Series B, ₩13.5B)
Key partnerships
Korea University Medical Center Industry-Academic Cooperation Foundation (technology transfer & joint development); Oracle Cloud Infrastructure (OCI) partnership (Miracle Program); Lotte Hotels (pilot program for senior facilities); IBK Changgong Guro 14th batch
Major milestones
2024: Founded as Korea University Medical Center faculty startup; Technology transfer from Korea University Medical Center; 2025: Seed investment from 5 investors; IBK Changgong Guro 14th batch selection; 2026: TIPS + Didimdol government grants simultaneous selection; World IT Show 2026 Innovation Award (Minister of Science and ICT Award); Korea Impact Tech Award (KAICA Chairman Award); Clinical trial with 124 patients across 5 institutions
Market positioning
Early-stage Korean digital health startup pioneering voice-based AI diagnostics for heart failure, positioned at the intersection of AI voice analysis and cardiology digital therapeutics
Geographic focus
South Korea (primary); Expanding to US, Japan, Singapore, China
Patents and IP
1 patent filed (published 2025-03-17, per THE VC)
About 정경호 (Jung Kyung-ho)
Ex-Aimmed DTx Business Division Head (led Korea's first DTx 'Somzz' for insomnia); Ex-Hanmi Healthcare E-Biz Division Head; Ministry of Food and Drug Safety Digital Medical Product Regulatory Innovation public-private committee member; Korea Medical Device Industry Association Innovation Industry Committee DTx subcommittee member
Official website: http://www.adotcure.com/